MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

Search

Novartis AG

Suletud

109.52 -1.67

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

109.36

Max

112.37

Põhinäitajad

By Trading Economics

Sissetulek

-369M

2.8B

Müük

386M

14B

P/E

Sektori keskmine

18.925

73.239

Aktsiakasum

1.98

Dividenditootlus

3.48

Kasumimarginaal

20.8

Töötajad

75,883

EBITDA

-426M

5.2B

Soovitused

By TipRanks

Soovitused

Neutraalne

12 kuu keskmine prognoos

-0.43% downside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

3.48%

3.06%

Turustatistika

By TradingEconomics

Turukapital

5.4B

219B

Eelmine avamishind

111.19

Eelmine sulgemishind

109.52

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

Novartis AG Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

11. veebr 2025, 06:57 UTC

Omandamised, ülevõtmised, äriostud

Novartis to Buy Anthos Therapeutics for Up to $3.08 Billion

31. jaan 2025, 09:49 UTC

Tulu

Novartis Expects Further Profit, Sales Growth Despite Competition Threat -- 2nd Update

31. jaan 2025, 08:06 UTC

Tulu

Novartis Expects Further Profit, Growth After Key Drugs Boost Sales -- Update

31. jaan 2025, 06:32 UTC

Tulu

Novartis Expects Further Profit, Growth After Key Drugs Boost Sales

17. märts 2025, 07:34 UTC

Market Talk

Novartis Growth Outlook Clouded by Patent Expiries, Pipeline Concerns -- Market Talk

4. märts 2025, 18:45 UTC

Tulu

Novartis Earnings Surprised The Street; Still Going Strong Despite Market Correction -- IBD

11. veebr 2025, 09:25 UTC

Peamised uudised
Omandamised, ülevõtmised, äriostud

Novartis to Buy Anthos Therapeutics From Blackstone for Up to $3.1 Billion -- Update

11. veebr 2025, 06:42 UTC

Peamised uudised
Omandamised, ülevõtmised, äriostud

Novartis to Buy Anthos Therapeutics for Up to $3.08 Bln

11. veebr 2025, 06:22 UTC

Omandamised, ülevõtmised, äriostud

Novartis: Acquisition Is Aligned With Strategic Focus on Cardiovascular Therapeutic Area

11. veebr 2025, 06:20 UTC

Omandamised, ülevõtmised, äriostud

Novartis: Abelacimab's Lead Indication Is Prevention of Stroke, Systemic Embolism

11. veebr 2025, 06:19 UTC

Omandamised, ülevõtmised, äriostud

Novartis: Anthos Is Developing Abelacimab, Currently in Late-Stage Trials

11. veebr 2025, 06:18 UTC

Omandamised, ülevõtmised, äriostud

Novartis: Deal Is Expected to Close in 1H of 2025

11. veebr 2025, 06:18 UTC

Omandamised, ülevõtmised, äriostud

Novartis Aims to Bolster Late-Stage Cardiovascular Pipeline With Acquisition

11. veebr 2025, 06:17 UTC

Omandamised, ülevõtmised, äriostud

Novartis: Deal Includes Potential Additional Payments of Up to $2.15B

11. veebr 2025, 06:16 UTC

Omandamised, ülevõtmised, äriostud

Novartis to Buy Anthos Therapeutics for $925M Upfront

11. veebr 2025, 06:15 UTC

Omandamised, ülevõtmised, äriostud

Novartis to Buy Anthos Therapeutics

4. veebr 2025, 15:16 UTC

Peamised uudised

Novartis Sets High Bar in Pursuit of Obesity Deals, CEO Says -- Interview

4. veebr 2025, 08:12 UTC

Market Talk
Tulu

Novartis Outlook Indicates No Patent Cliff Beyond 2025 -- Market Talk

31. jaan 2025, 13:56 UTC

Tulu

Novartis Edges Higher On Sales Beat As Competition Looms For Its Biggest Moneymaker -- IBD

31. jaan 2025, 09:59 UTC

Kuumad aktsiad

Stocks to Watch Friday: Intel, Apple, Vertex, Samsung -- WSJ

31. jaan 2025, 07:50 UTC

Market Talk

Novartis's Outlook Exceeds Market Views -- Market Talk

31. jaan 2025, 07:46 UTC

Market Talk
Tulu

Novartis's Results Beat Could Clear Gap Between Mid-Term Outlook and Market Views -- Market Talk

31. jaan 2025, 06:03 UTC

Tulu

Novartis Expects 2025 Core Operating Profit Growth of High Single to Low Double-Digit at Constant Currency

31. jaan 2025, 06:02 UTC

Tulu

Novartis Expects 2025 Net Sales Growth of mid- to high-single Digit at Constant Currency

31. jaan 2025, 06:02 UTC

Tulu

Novartis Issues 2025 View

31. jaan 2025, 06:02 UTC

Tulu

Novartis Raises Dividend to CHF3.50 Vs CHF3.30

31. jaan 2025, 06:02 UTC

Tulu

Novartis 4Q Oper Pft $3.53B

31. jaan 2025, 06:02 UTC

Tulu

Novartis 4Q Net Pft $2.82B

31. jaan 2025, 06:02 UTC

Tulu

Analysts Saw Novartis 4Q Core Operating Profit at $4.44B

31. jaan 2025, 06:02 UTC

Tulu

Novartis 4Q Core Operating Profit $4.86B

Võrdlus sarnastega

Hinnamuutus

Novartis AG Prognoos

Hinnasiht

By TipRanks

-0.43% langus

12 kuu keskmine prognoos

Keskmine 111 USD  -0.43%

Kõrge 125 USD

Madal 97 USD

Põhineb 2 Wall Streeti analüütiku instrumendi Novartis AG 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

2 ratings

0

Osta

2

Hoia

0

Müü

Tehniline skoor

By Trading Central

108.6463 / 111.415Toetus ja vastupanu

Lühikene perspektiiv

Bearish Evidence

Keskpikk perspektiiv

Bullish Evidence

Pikk perspektiiv

Strong Bullish Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Novartis AG

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. The company has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. It also has a research collaboration and license agreement with Schrödinger, Inc. to identify and develop various therapeutic candidates; and a strategic collaboration with Vyriad, Inc. for the discovery and development for vivo chimeric antigen receptor T-cell therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.